At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Lenalidomide +2 moredrug
Likely dose
R-CHOP 375 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study
In Brief
A Phase 2 clinical trial evaluating Lenalidomide, R-CHOP, and 1 other intervention for Mantle Cell Lymphoma and Untreated. Completed, enrolled 49 participants across 7 sites.
Detailed Summary
The purpose of this study is to find out what effects, good and/or bad, the treatment including 1) Lenalidomide-RCHOP, 2) R-HIDAC, and 3) Lenalidomide-Rituximab maintenance has on the participant and their lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMantle Cell Lymphoma, Untreated
CountriesUnited States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedDec 2015
Primary CompletionNov 2023
TodayJul 2026
First PostedDec 17, 2015
Enrollment StartDec 14, 2015
Primary CompletionNov 7, 2023
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 10.5 years ago
Interventions
Lenalidomidedrug
R-CHOPdrug
* Rituximab 375 mg/m\^2 IVPB with premedications Day 1 * Cyclophosphamide 750 mg/m\^2 IVPB Day 1 * Doxorubicin 50 mg/m\^2 IVP Day 1 * Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1 * Prednisone 100 mg PO Daily on Days 1-5 or 2-6
high-dose cytarabine (HIDAC)drug